A US-headquartered biotechnology company, Kineta, and
The company said that ACT makes a new funding model to accelerate research for its potential use by pediatric patients.
Hendricks said, "30% of the U.S. population is under the age of 21, and yet only 6% of the entire
The company said that there are barriers in developing pediatric therapies and the lack of pediatric medication use information poses risks to teens and children.
ACT brings together one of the US's top five pediatric research institutions with a leading biotechnology firm. The goal is to speed up development of medicines for teens and children with autoimmune diseases.
Most Popular Stories
- What Hamas and Israel Hope to Gain in Gaza
- Homeowners More Satisfied With Mortgage Servicers
- House Shelves Immigration Bill, Goes on Vacation
- NASA Plans to Make Oxygen on Mars
- Why Samsung Shares Plunged in the April-June Quarter
- House GOP Leaders Abandon Immigrant Bill
- Notorious RBG Tells All in Couric Interview
- Wisconsin Supreme Court: Voter IDs Must Be Free
- Ford Tremor: Easy to Park, Hard to Pay For
- Market Loses All of July's Gains in One Day